Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2022 | Treatments for HER2+ esophagogastric cancer

Per Pfeiffer • 27 Jun 2022
ESMO WCGIC 2022
Gastroesophageal Cancer Gastrointestinal Cancer Antibodies Trastuzumab Trastuzumab deruxtecan

Per Pfeiffer, MD, PhD, Odense University Hospital and University of Southern Denmark, Odense, Denmark, discusses recent research into treatments for patients with HER2+ esophagogastric cancer, including the approval of trastuzumab plus chemotherapy. Prof. Pfeiffer emphasises the promising future of combination immunotherapy and chemotherapy for these patients. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.

More from Per Pfeiffer

3:54
TAS-102 plus bevacizumab vs. TAS-102 alone for previously treated metastatic esophagogastric cancer
Per Pfeiffer • 27 Jun 2022

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals